 risk of bleeding.133
It should be noted that only a subset of participants in
this trial had PAD, of which only 21% had diabetes. Also, a
meta-analysis did not show any beneÔ¨Åt from aspirin for
those with PAD.134 A post hoc subanalysis of the CAPRIE
trial showed that clopidogrel was superior to aspirin in
reducing recurrent ischaemic events in those with diabetes.13